Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment

Zheng, WW; Zhou, H; Li, P; Ye, SG; Abudureheman, T; Yang, LT; Qing, K; Liang, AB; Chen, KM; Duan, CW

Chen, KM; Duan, CW (通讯作者),Shanghai Jiao Tong Univ, Minist Hlth, Key Lab Pediat Hematol & Oncol, Shanghai Childrens Med Ctr,Sch Med, Shanghai, Peoples R China.;Chen, KM; Duan, CW (通讯作者),Shanghai Jiao Tong Univ, Pediat Translat Med Inst, Sch Med, Shanghai Childrens Med Ctr, Shanghai, Peoples R China.;Duan, CW (通讯作者),Youjiang Med Univ Nationalities, Dept Pathol, Affiliated Hosp, Baise, Peoples R China.;Liang, AB (通讯作者),Tongji Univ, Tongji Hosp, Dept Hematol, Sch Med, Shanghai 200092, Peoples R China.;Chen, KM; Duan, CW (通讯作者),Shanghai Jiao Tong Univ, Fujian Branch, Shanghai Childrens Med Ctr, Sch Med, Fuzhou, Peoples R China.;Chen, KM; Duan, CW (通讯作者),Fujian Childrens Hosp, Fuzhou, Peoples R China.;Duan, CW (通讯作者),Fujian Matern & Child Hlth Hosp, Key Lab Tech Evaluat Fertil Regulat Nonhuman Prim, Natl Hlth Commiss, Fuzhou, Peoples R China.

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023; 72 (11): 3739

Abstract

CD19 CAR-T (chimeric antigen receptor-T) cell immunotherapy achieves a remission rate of approximately 70% in recurrent and refractory lymphoma treatm......

Full Text Link